Consensus Metagenomi, Inc.

Equities

Delayed Nasdaq Other stock markets 18:51:18 06/06/2024 BST			5-day change	1st Jan Change
6.58 ^USD	+0.46%		+2.97%	0.00%

05-14	Metagenomi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target	MT

de87f27596598.LAUg1sZfBH4gnJoWsyeto3N_r8FOkmVee_nr0tg_9nc.bU5huqwHVRBQ2sVc53DblSY-7oos5CAOSKOyqq4HpxtifUOEmTliK3Kpww~ca3b4bec260e4903d19e9b9307d33619

HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target	05-07	MT
Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating	05-02	MT
JPMorgan Downgrades Metagenomi to Neutral, Price Target at $6	05-02	MT
TD Cowen Initiates Metagenomi With Outperform Rating	03-05	MT
Jefferies Starts Metagenomi With Buy Rating, $23 Price Target	03-05	MT
BMO Capital Starts Metagenomi With Outperform Rating, $22 Price Target	03-05	MT
Wells Fargo Starts Metagenomi With Overweight Rating, $25 Price Target	03-05	MT
JPMorgan Starts Metagenomi With Overweight Rating, $16 Price Target	03-05	MT
Chardan Starts Metagenomi With Buy Rating, Price Target is $21	03-05	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.55 USD

Average target price

16.83 USD

Spread / Average Target

+157.00%

High Price Target

25 USD

Spread / Highest target

+281.68%

Low Price Target

6 USD

Spread / Lowest Target

-8.40%